Multi-Million Dollar Effort To Improve US Health Care To Be Announced By Robert Wood Johnson Foundation Disparate quality care nationwide spurs largest
health care philanthropy to attack the problem in communities across AmericaWhat: Announcement of a multi-million dollar investment to improve quality in 14 regions nationwide New Dartmouth Atlas data, commissioned for the Aligning Forces fo
Source: www.medicalnewstoday.comAbbott Contributes To Disaster Relief Efforts In China And Myanmar Abbott and its philanthropic foundation Abbott Fund are providing U.S. $1.5 million in humanitarian aid in response to the earthquake in Sichuan Province in China and Cyclone Nargis in Myanmar. Abbott is working with its humanitarian aid organization partners with an established presence on the ground in China and Myanmar.
Source: www.medicalnewstoday.comBARC Announces Long-Term Cooperation In South African Biobanking For HIV Vaccine Trials BARC, a global central laboratory announced a broad biobanking agreement to support HIV vaccine trials currently being performed in South Africa by the HIV Vaccine Trials Network (HVTN). The HVTN vaccine trials are designed to answer scientific questions that will advance knowledge and ultimately lead to a safe and effective vaccine to prevent HIV infection.
Source: www.medicalnewstoday.comWyeth Receives Approvable Letter From FDA For Bazedoxifene For The Treatment Of Postmenopausal Osteoporosis Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced that the U.S. Food and Drug Administration (FDA) issued an approvable letter on May 21 for bazedoxifene, a selective estrogen receptor modulator, for the treatment of postmenopausal osteoporosis.
Source: www.medicalnewstoday.comExploring The Genetic Variation Of HIV-1 A review article in the New England Journal of
Medicine explores the genetic variation of HIV-1 and its implications for preventing and treating the disease. Francine McCutchan, Ph.D., a researcher with the U.S. Military HIV Research Program, co-authored the article.HIV-1 is classified into several subtypes, or clades, which are denoted by letters.
Source: www.medicalnewstoday.comPalatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL 3994 Palatin Technologies, Inc. (Amex: PTN) announced that dosing has been initiated in a Phase 2a clinical study of PL-3994, a novel, long-acting natriuretic peptide receptor A agonist, in subjects with controlled hypertension. The study is placebo-controlled and double-blinded, and will include up to five cohorts receiving escalating doses.
Source: www.medicalnewstoday.com$11.6M NIH Grant To Study Novel Mechanisms Of Heart Failure Received By Jefferson Scientists at Jefferson Medical College have received a five-year, $11.6 million grant from the National Heart, Lung and Blood Institute to study molecular mechanisms of cardiac injury that lead to heart failure and potential repair processes that occur in the adult failing heart. This project aims to find data that can be translated into novel therapeutic strategies to improve the failing heart.
Source: www.medicalnewstoday.comData Show Rufinamide, An Investigational Adjunctive Treatment For Lennox- Gastaut Syndrome, Reduced Drop Attacks By More Than 40% Eisai Corporation of North America announced the publication of a placebo-controlled study in Neurology that found patients with Lennox-Gastaut syndrome (LGS) treated with the investigational antiepileptic agent rufinamide as adjunctive therapy experienced more than 40% fewer drop attacks than patients who received placebo (increase of 1.4%).
Source: www.medicalnewstoday.comCirculation: Heart Failure: New Journal Focuses On Progress, Problems In Treating Heart Failure Findings about how the day of admission influences the length of a patient's hospitalization for heart failure, and questions about the effectiveness of two
drugs to treat heart failure patients are featured in the inaugural issue of Circulation: Heart Failure.
Source: www.medicalnewstoday.comFirst Pre Pandemic Vaccine Approved To Help Protect Against Pandemic Influenza GlaxoSmithKline (GSK plc) announced that the European Commission has granted a marketing authorisation for its H5N1 adjuvanted pre-pandemic vaccine, Prepandrix?, in all 27 EU member states.
Source: www.medicalnewstoday.comLabels: No Prescription, Online Pharmacy
# posted by Network @ 6:00 PM
